GENA BYRD-TURNER: Open Payments
NPI 1932775632 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 32 payments from 10 companies in 2025. Trend: 2023 $255 · 2024 $18 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $98 |
| Novartis Pharmaceuticals Corporation | 4 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| CSL Behring | 4 | $66 |
| GlaxoSmithKline, LLC. | 3 | $62 |
| Amgen Inc. | 3 | $57 |
| Grifols USA, LLC | 1 | $27 |
| BioCryst US Sales Co., LLC | 1 | $22 |
Products named: TEZSPIRE, CUVITRU, NEFFY, DUPIXENT, Rhapsido, AIRSUPRA, TRELEGY ELLIPTA, Andembry.
Industry payments across MD — which companies pay providers there.
